跳转至内容
Merck
  • Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.

Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.

Diabetes research and clinical practice (2018-07-22)
Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel
摘要

The two dipeptidyl peptidase (DPP)-4 inhibitors, linagliptin and sitagliptin, were shown to exert different binding kinetics in vitro. Twenty-four hours after oral dosing particularly in vivo inhibition of renal-specific DPP-4 activity was more sustained in Sprague Dawley rats after exposure to linagliptin than it was after sitagliptin.

材料
货号
品牌
产品描述

Sigma-Aldrich
Gly-Pro 4-甲氧基-β-萘酰胺, dipeptidylpeptidase IV substrate